STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2309 by analyst upside · 2026-08-14
GMED
Globus Medical, Inc.
Healthcare · Market Cap $12B · P/E 22.0x
ANALYST PRICE TARGET
+20.1%
implied upside to consensus target
Current Price $85.94
Consensus Target $103.23
Bull Target $125.0
Bear Target $84.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
4
Sell
0
52-Week Low $54.15
52-Week High $101.4
YTD Return -1.6%
FUNDAMENTALS
Market Cap $12B
P/E Ratio (TTM) 22.0x
Forward P/E 16.0x
EPS (TTM) $3.91
PEG Ratio 1.49
Dividend Yield N/A
Revenue (TTM) $3.1B
Profit Margin 17.0%
52-WEEK RANGE
52-Week Low $54.15
52-Week High $101.4
Current Price $85.94
Bear Target $84.0
Bull Target $125.0
● Now $85.94 ● Target $103.23
TRADING DATA
Avg Volume 1.8M
YTD Return -1.6%
Analyst Count 13
Consensus Buy
Upside to Target +20.1%
Last Updated 2026-08-14

ANALYST SUMMARY

Globus Medical, Inc. (GMED) is currently trading at $85.94 with a Wall Street consensus price target of $103.23, implying potential upside of 20.1% over the next 12 months. 13 analysts currently cover GMED, with a consensus rating of Buy - 69% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $125.0, while the most cautious has a target of $84.0.

GMED operates in the Healthcare sector with a market capitalisation of $12B. The stock is down 1.6% year-to-date and is currently trading near the upper end of its 52-week range of $54.15 – $101.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GMED, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-06-15 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-05-08 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-08 Building track record
Needham - Reiterated
Buy → Buy 2026-05-08 20% win rate (5 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-02-26 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-02-25 Building track record
Needham - Reiterated
Buy → Buy 2026-02-25 20% win rate (5 calls)
Needham ↑ Upgrade
Hold → Buy 2026-01-30 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
20/30
Consensus clarity
20/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →